Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11222090 | 0.87 | PDPK1 (0.32) | PDPK1GDA | |
| SCHEMBL6379581 | 0.86 | HRH2 (0.37) | PDPK1GDA | |
| SCHEMBL5066802 | 0.84 | ADORA1 (0.37) | PDPK1GDA | |
| SCHEMBL9176115 | 0.84 | GDA (0.32) | PDPK1GDA | |
| SCHEMBL766489 | 0.83 | HRH3 (0.35) | PDPK1 | |
| SCHEMBL215053 | 0.81 | ADORA2A (0.40) | — | |
| SCHEMBL38911 | 0.80 | HRH1 (0.38) | PDPK1 | |
| SCHEMBL20744783 | 0.80 | — | — | |
| SCHEMBL3957290 | 0.80 | CDK1 (0.33) | — | |
| SCHEMBL6029478 | 0.80 | CASP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | PDPK1 4669/4885GDA 165/4885DPP4 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.